FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3137605561> ?p ?o ?g. }

• W3137605561 endingPage "100077" @default.
• W3137605561 startingPage "100077" @default.
• W3137605561 abstract "•This final analysis reconfirmed that SOX is not superior to UFT/LV in high-risk stage III colon cancer in terms of DFS.•With a median follow-up time of 74.3 months, the 5-year OS rate was similar in both groups.•The 5-year OS rates in patients with T4N2b disease were 51.0% and 64.1% in the UFT/LV and SOX groups, respectively. BackgroundThe ACTS-CC 02 trial demonstrated that S-1 plus oxaliplatin (SOX) was not superior to tegafur-uracil and leucovorin (UFT/LV) in terms of disease-free survival (DFS) as adjuvant chemotherapy for high-risk stage III colon cancer (any T, N2, or positive nodes around the origin of the feeding arteries). We now report the final overall survival (OS) and subgroup analysis according to the pathological stage (TNM 7th edition) for treatment efficacy.Patients and methodsPatients who underwent curative resection for pathologically confirmed high-risk stage III colon cancer were randomly assigned to receive either UFT/LV (300 mg/m2 of UFT and 75 mg/day of LV on days 1-28, every 35 days, five cycles) or SOX (100 mg/m2 of oxaliplatin on day 1 and 80 mg/m2/day of S-1 on days 1-14, every 21 days, eight cycles). The primary endpoint was DFS and the patients’ data were updated in February 2020.ResultsA total of 478 patients in the UFT/LV group and 477 patients in the SOX group were included in the final analysis. With a median follow-up time of 74.3 months, the 5-year DFS rate was 55.2% in the UFT/LV group and 58.1% in the SOX group [stratified hazard ratio (HR) 0.92; 95% confidence interval (CI) 0.76-1.11; P = 0.3973], and the 5-year OS rates were 78.3% and 79.1%, respectively (stratified HR 0.97; 95% CI 0.76-1.24; P = 0.8175). In the subgroup analysis, the 5-year OS rates in patients with T4N2b disease were 51.0% and 64.1% in the UFT/LV and SOX groups, respectively (HR 0.72; 95% CI 0.40-1.31).ConclusionOur final analysis reconfirmed that SOX as adjuvant chemotherapy is not superior to UFT/LV in terms of DFS in patients with high-risk stage III colon cancer. The 5-year OS rate was similar in the UFT/LV and SOX groups. The ACTS-CC 02 trial demonstrated that S-1 plus oxaliplatin (SOX) was not superior to tegafur-uracil and leucovorin (UFT/LV) in terms of disease-free survival (DFS) as adjuvant chemotherapy for high-risk stage III colon cancer (any T, N2, or positive nodes around the origin of the feeding arteries). We now report the final overall survival (OS) and subgroup analysis according to the pathological stage (TNM 7th edition) for treatment efficacy. Patients who underwent curative resection for pathologically confirmed high-risk stage III colon cancer were randomly assigned to receive either UFT/LV (300 mg/m2 of UFT and 75 mg/day of LV on days 1-28, every 35 days, five cycles) or SOX (100 mg/m2 of oxaliplatin on day 1 and 80 mg/m2/day of S-1 on days 1-14, every 21 days, eight cycles). The primary endpoint was DFS and the patients’ data were updated in February 2020. A total of 478 patients in the UFT/LV group and 477 patients in the SOX group were included in the final analysis. With a median follow-up time of 74.3 months, the 5-year DFS rate was 55.2% in the UFT/LV group and 58.1% in the SOX group [stratified hazard ratio (HR) 0.92; 95% confidence interval (CI) 0.76-1.11; P = 0.3973], and the 5-year OS rates were 78.3% and 79.1%, respectively (stratified HR 0.97; 95% CI 0.76-1.24; P = 0.8175). In the subgroup analysis, the 5-year OS rates in patients with T4N2b disease were 51.0% and 64.1% in the UFT/LV and SOX groups, respectively (HR 0.72; 95% CI 0.40-1.31). Our final analysis reconfirmed that SOX as adjuvant chemotherapy is not superior to UFT/LV in terms of DFS in patients with high-risk stage III colon cancer. The 5-year OS rate was similar in the UFT/LV and SOX groups." @default.
• W3137605561 created "2021-03-29" @default.
• W3137605561 creator A5009698073 @default.
• W3137605561 creator A5010090426 @default.
• W3137605561 creator A5010999012 @default.
• W3137605561 creator A5018138745 @default.
• W3137605561 creator A5019390917 @default.
• W3137605561 creator A5020121296 @default.
• W3137605561 creator A5024247368 @default.
• W3137605561 creator A5025399736 @default.
• W3137605561 creator A5027999029 @default.
• W3137605561 creator A5028322085 @default.
• W3137605561 creator A5033008284 @default.
• W3137605561 creator A5044992546 @default.
• W3137605561 creator A5049313696 @default.
• W3137605561 creator A5059829141 @default.
• W3137605561 creator A5062366532 @default.
• W3137605561 creator A5071189253 @default.
• W3137605561 creator A5076094269 @default.
• W3137605561 creator A5076910510 @default.
• W3137605561 creator A5081174788 @default.
• W3137605561 creator A5081294000 @default.
• W3137605561 creator A5083988552 @default.
• W3137605561 date "2021-04-01" @default.
• W3137605561 modified "2023-10-01" @default.
• W3137605561 title "S-1 and oxaliplatin versus tegafur-uracil and leucovorin as post-operative adjuvant chemotherapy in patients with high-risk stage III colon cancer: updated 5-year survival of the phase III ACTS-CC 02 trial" @default.
• W3137605561 cites W2100258195 @default.
• W3137605561 cites W2105064110 @default.
• W3137605561 cites W2115735904 @default.
• W3137605561 cites W2118415193 @default.
• W3137605561 cites W2118950501 @default.
• W3137605561 cites W2121847974 @default.
• W3137605561 cites W2125016589 @default.
• W3137605561 cites W2138985803 @default.
• W3137605561 cites W2147834058 @default.
• W3137605561 cites W2171232394 @default.
• W3137605561 cites W242040007 @default.
• W3137605561 cites W2592411288 @default.
• W3137605561 cites W2765911847 @default.
• W3137605561 cites W2766503667 @default.
• W3137605561 cites W2895246260 @default.
• W3137605561 cites W2897618102 @default.
• W3137605561 cites W2919626362 @default.
• W3137605561 cites W2944044607 @default.
• W3137605561 cites W2953428751 @default.
• W3137605561 cites W2980944134 @default.
• W3137605561 cites W3081064000 @default.
• W3137605561 doi "https://doi.org/10.1016/j.esmoop.2021.100077" @default.
• W3137605561 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7966838" @default.
• W3137605561 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33714860" @default.
• W3137605561 hasPublicationYear "2021" @default.
• W3137605561 type Work @default.
• W3137605561 sameAs 3137605561 @default.
• W3137605561 citedByCount "3" @default.
• W3137605561 countsByYear W31376055612022 @default.
• W3137605561 countsByYear W31376055612023 @default.
• W3137605561 crossrefType "journal-article" @default.
• W3137605561 hasAuthorship W3137605561A5009698073 @default.
• W3137605561 hasAuthorship W3137605561A5010090426 @default.
• W3137605561 hasAuthorship W3137605561A5010999012 @default.
• W3137605561 hasAuthorship W3137605561A5018138745 @default.
• W3137605561 hasAuthorship W3137605561A5019390917 @default.
• W3137605561 hasAuthorship W3137605561A5020121296 @default.
• W3137605561 hasAuthorship W3137605561A5024247368 @default.
• W3137605561 hasAuthorship W3137605561A5025399736 @default.
• W3137605561 hasAuthorship W3137605561A5027999029 @default.
• W3137605561 hasAuthorship W3137605561A5028322085 @default.
• W3137605561 hasAuthorship W3137605561A5033008284 @default.
• W3137605561 hasAuthorship W3137605561A5044992546 @default.
• W3137605561 hasAuthorship W3137605561A5049313696 @default.
• W3137605561 hasAuthorship W3137605561A5059829141 @default.
• W3137605561 hasAuthorship W3137605561A5062366532 @default.
• W3137605561 hasAuthorship W3137605561A5071189253 @default.
• W3137605561 hasAuthorship W3137605561A5076094269 @default.
• W3137605561 hasAuthorship W3137605561A5076910510 @default.
• W3137605561 hasAuthorship W3137605561A5081174788 @default.
• W3137605561 hasAuthorship W3137605561A5081294000 @default.
• W3137605561 hasAuthorship W3137605561A5083988552 @default.
• W3137605561 hasBestOaLocation W31376055611 @default.
• W3137605561 hasConcept C121608353 @default.
• W3137605561 hasConcept C126322002 @default.
• W3137605561 hasConcept C141071460 @default.
• W3137605561 hasConcept C143998085 @default.
• W3137605561 hasConcept C146357865 @default.
• W3137605561 hasConcept C151730666 @default.
• W3137605561 hasConcept C203092338 @default.
• W3137605561 hasConcept C2776694085 @default.
• W3137605561 hasConcept C2777299880 @default.
• W3137605561 hasConcept C2780456651 @default.
• W3137605561 hasConcept C2780962732 @default.
• W3137605561 hasConcept C526805850 @default.
• W3137605561 hasConcept C535046627 @default.
• W3137605561 hasConcept C71924100 @default.
• W3137605561 hasConcept C86803240 @default.
• W3137605561 hasConcept C90924648 @default.
• W3137605561 hasConceptScore W3137605561C121608353 @default.
• W3137605561 hasConceptScore W3137605561C126322002 @default.
• W3137605561 hasConceptScore W3137605561C141071460 @default.

• next